Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes

Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes

ABSTRACT Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Junko Oya, Mika Shimizu, Ryo Kubota, Rika Suda, Tomoko Nagkagami
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	Journal of Diabetes Investigation
Subjects:	Dipeptidyl peptidase‐4 inhibitor Oral semaglutide Real‐world clinical setting
Online Access:	https://doi.org/10.1111/jdi.14391
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Targeting dipeptidyl peptidase-8/9 to combat inflammation-induced osteoclastogenesis in RAW264.7 macrophages and analysis of anti-osteoclastogenesis potential of chrysin
by: Syed Sufian Ahmad, et al.
Published: (2025-04-01)

Dataset on effect of cadmium and lead on chemical reactivity of selected heterocyclic compounds as potential dipeptidyl peptidase III inhibitors using insilico methodMendeley Data
by: Kehinde Adeola Bolaji, et al.
Published: (2025-06-01)

Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland
by: David Alexander Dickie, et al.
Published: (2025-05-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: M Elle Saine, et al.
Published: (2015-04-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Enzymatic hydrolysis of buffalo casein enhances DPP-4 inhibition: Structural modifications and bioactive peptide identification
by: Ning An, et al.
Published: (2025-03-01)

Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
by: Arunkumar Krishnan, et al.
Published: (2024-12-01)

Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism of <i>Aspergillus fumigatus</i>
by: Marion Filliâtre, et al.
Published: (2025-07-01)

Elimination of hepatocyte‐derived DPP4 downregulates cardiac immune‐ and collagen‐related genes but does not alter cardiac function in aged male mice
by: Natasha A. Trzaskalski, et al.
Published: (2025-08-01)

Bio-Adrenomedullin and Dipeptidyl Peptidase 3 as Novel Sepsis Biomarkers in the Emergency Department and the Intensive Care Unit: A Narrative Review
by: Ioannis Ventoulis, et al.
Published: (2025-06-01)

Protein hydrolysate as a source of bioactive peptides in diabetic food products
by: O. V. Zinina, et al.
Published: (2024-01-01)

Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01)

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas
by: Wei‐Sheng Chen, et al.
Published: (2025-03-01)

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study
by: Yu-Ching Li, et al.
Published: (2025-04-01)

Spotlight on the Mechanism of Action of Semaglutide
by: Ilias Papakonstantinou, et al.
Published: (2024-12-01)

From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use
by: Rawan Othman
Published: (2025-08-01)

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study
by: Makoto Ohara, et al.
Published: (2025-04-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)

Research progress on the association of bullous pemphigoid with type 2 diabetes mellitus
by: ZHANG Ruohan, et al.
Published: (2025-03-01)

Deciphering new biomolecules, antioxidants, and human dipeptidyl Peptidase-4 inhibitor potential of green celery: Bioprospecting insights from molecular docking and in vitro investigation
by: Fan Maitri Aldian, et al.
Published: (2025-10-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Curcumin inhibits growth of Porphyromonas gingivalis by arrest of bacterial dipeptidyl peptidase activity
by: Hiroki Murai, et al.
Published: (2024-12-01)

Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data
by: Cristina Hernández, et al.
Published: (2024-11-01)

Preparation and Purification of Dipeptidyl Peptidase-IV Inhibitory Peptides from Pearl Mussel Muscle
by: ZHANG Chuhan, CHEN Yinge, MA Ting, WENG Ling, ZHANG Lingjing, ZHANG Genfang, CAO Minjie
Published: (2024-09-01)

Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01)

Contractile Effects of Semaglutide in the Human Atrium
by: Joachim Neumann, et al.
Published: (2024-08-01)

Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01)

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
by: Mohamad Suki, et al.
Published: (2025-07-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
by: Marine Massy, et al.
Published: (2025-04-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
by: Kenneth Brand, et al.
Published: (2025-04-01)

Angioedema following venipuncture in a patient on angiotensin‐converting enzyme inhibitor and dipeptidyl peptidase‐IV inhibitor therapy: A case report
by: Adrien Bénic, et al.
Published: (2025-06-01)

Role of DPP-4 and NPY Family Peptides in Gastrointestinal Symptoms Associated with Obesity and Type 2 Diabetes Mellitus
by: Mantas Malinauskas, et al.
Published: (2025-03-01)

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
by: Yaswanth Kuthati, et al.
Published: (2025-04-01)

Case Report: Treatment of delayed tremor episodes in a patient with DPPX antibody encephalitis
by: Miao Yu, et al.
Published: (2025-07-01)

Hypoglycemic Therapy and the Course of Post-Covid Syndrome, is There a Connection?
by: G. A. Ignatenko, et al.
Published: (2023-04-01)